TPP Trade Deal Sealed: Did Brand-Name Biopharma Really Lose?
This article was originally published in SRA
Executive Summary
After more than six years of intense efforts to lobby a group of Asia-Pacific trade ministers - a pact that eventually involved representatives from 12 nations - the innovator biopharmaceutical industry failed to get what it most wanted in the Trans-Pacific Partnership (TPP): 12 years of data exclusivity protection for biologics against biosimilars1,2.